Overview
(July 7, 2023, New Jersey) – The US District Court for the District of New Jersey ruled in favor of Orexo in its Hatch-Waxman litigation against Sun regarding Zubsolv®, a novel buprenorphine and naloxone sublingual tablet used for the treatment of opioid dependence. Following a five-day trial, the district court issued an opinion in favor of Orexo on all issues, finding that Sun infringed Orexo’s asserted patents and that those patents were valid.
This victory was of particular importance to Orexo given that Zubsolv® is a foundational product upon which Orexo relies to fund its ongoing efforts to develop innovative new products for treating drug dependence and mental health issues.
The Steptoe team representing Orexo was led by partner John Molenda, and included partners Vishal Gupta and Jordan Markham; counsel Lawrence Kass; associates Tyler Doh, Lillian Wallace, Michael Green, and Darpan Patel; and law clerk Yun Zhang.
About Steptoe
In more than 100 years of practice, Steptoe has earned an international reputation for vigorous representation of clients before governmental agencies, successful advocacy in litigation and arbitration, and creative and practical advice in structuring business transactions. Steptoe has more than 500 lawyers and other professional staff across offices in Beijing, Brussels, Chicago, Hong Kong, London, Los Angeles, New York, San Francisco, and Washington. For more information, visit www.steptoe.com.
